Wilson M, Wasserman M, Breton MC, Peloquin F, McDade C, Earnshaw S, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Quebec. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada.
Wasserman M, Wilson M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Previously presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases.
Breton MC, Peloquin F, Wasserman M, Wilson M, McDade C, Farkouh R. Pneumococcal vaccination provides substantial value for money for Canadians. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada. Previously presented at the IDWeek 2017 Conference.
Breton MC, Farkouh R, Vojicic J, Wilson M, McDade C, Wasserman M. Modeling reductions in antibiotic prescriptions due to otitis media in Canada as a result of pneumococcal vonjugate vaccination. Poster presented at the IDWeek 2018 Conference; October 5, 2018. San Francisco, CA.
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1
Wilson M, Wasserman M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.